Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE2 | P0DPD6 | 2/20 | 1.00 |
| ▸ | ECE1 | P42892 | 2/20 | 1.00 |
| ▸ | MUS81 | Q96NY9 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 0.89 |
| ▸ | PGR | P06401 | 1/20 | 0.73 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.70 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.67 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16653949 | 1.00 | ECE2 (1.00) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL4570235 | 1.00 | ECE2 (1.00) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL29370806 | 1.00 | ECE2 (1.00) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL29695489 | 1.00 | ECE2 (1.00) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL29695645 | 1.00 | ECE2 (1.00) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL16653952 | 1.00 | ECE2 (1.00) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL14983767 | 0.94 | AR (1.00) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL1175104 | 0.87 | AR (0.82) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL1175103 | 0.87 | AR (0.82) | ECE2ECE1MUS81ARPGR | |
| SCHEMBL29874298 | 0.87 | AR (0.82) | ECE2ECE1MUS81ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068705-A1 | METHOD OF PREPARING A NUCLEIC ACID SAMPLE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-04-03 | — | — | WO | claimed |
| US-20250382375-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF | DYNE THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| WO-2025068705-A1 | METHOD OF PREPARING A NUCLEIC ACID SAMPLE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-04-03 | — | — | WO | disclosed |
| EP-4311546-A1 | COMBINATION THERAPY FOR MYOPATHIES | Dynacure (FR) | 2024-01-31 | — | — | EP | disclosed |
| EP-4215614-A1 | COMBINATION THERAPY FOR DYSTROPHIN-RELATED DISEASES | Dynacure (FR) | 2023-07-26 | — | — | EP | disclosed |
| EP-4185329-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF | Dyne Therapeutics, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-116194470-A | Muscle targeting complexes and uses thereof | 达因疗法公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-4121053-A1 | COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURRENCE OF A CORONAVIRIDAE INFECTION | ABIVAX (FR) | 2023-01-25 | — | — | EP | disclosed |
| CN-115605205-A | Compounds for treating or preventing infections of the family coronaviridae and methods and uses for assessing the occurrence of infections of the family coronaviridae | ABIVAX公司（FR） | 2023-01-13 | — | — | CN | disclosed |
| CN-115427448-A | Muscle targeting complexes and uses thereof | 达因疗法公司 | 2022-12-02 | — | — | CN | disclosed |
| EP-4087876-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF | Dyne Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382375-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF | MUSK, MYOF, MYLK2 | ECE2 1850/4885ECE1 1919/4885MUS81 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.